Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Aug 10, 2015
Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results

Aug 6, 2015
Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development

Aug 3, 2015
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call

Jun 25, 2015
U.S. FDA Grants Priority Review for MM-398 New Drug Application

View all »Events & Presentations

Sep 9, 2015
Citi 10th Annual Biotech Conference

Nov 9, 2015
2015 Credit Suisse Healthcare Conference

Nov 16, 2015
Brean Capital 2015 Life Sciences Summit

Stock Quote (NASDAQ: MACK)

Price:
10.62

Change:
+ 0.19

Day High:
11.00

Day Low:
10.31

Volume:
1,992,000

2:52 PM ET on Aug 28, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools